Gritstone Oncology Inc. Stock News

Cognition Therapeutics (NASDAQ:CGTX) and Gritstone bio (NASDAQ:GRTS) are both small-cap companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability. Earnings & Valuation This table compares Cognition Therapeutics and Gritstone bios top-line revenue, earnings per share []

EMERYVILLE, Calif. and OSLO, Norway, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing next generation cancer and infectious disease immunotherapies, and CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the expansion of their agreement in order to support the development of a self-amplifying mRNA (SAM) vaccine designed to tackle the Omicron COVID-19 variant. CEPI will provide up to $5 million in additional funding to conduct a Phase 1 clinical trial of Gritstones Omicron vaccine candidate in South Africa, where a CEPI-funded clinical trial of Gritstones Beta variant COVID-19 vaccine is due to begin shortly. The SARS-CoV-2 T cell epitopes (TCEs) administered within Gritstones SAM COVID-19 vaccines are minimally impacted by mutations found within the Omicron variant, reinforcing the platforms potential to address both Omicron and future variants of concern.

Gritstone bio, Inc. (NASDAQ:GRTS) COO Erin Jones sold 1,000 shares of the businesss stock in a transaction that occurred on Wednesday, December 1st. The shares were sold at an average price of $13.01, for a total transaction of $13,010.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through []

Gritstone bio, Inc. (NASDAQ:GRTS) shares saw unusually-high trading volume on Wednesday . Approximately 37,656 shares changed hands during trading, a decline of 98% from the previous sessions volume of 1,521,021 shares.The stock last traded at $13.34 and had previously closed at $13.20. GRTS has been the subject of several recent research reports. Zacks Investment Research [] The post Gritstone bio (NASDAQ:GRTS) Sees Unusually-High Trading Volume appeared first on ETF Daily News .

Investors need to pay close attention to Gritstone (GRTS) stock based on the movements in the options market lately.

Investors need to pay close attention to Gritstone (GRTS) stock based on the movements in the options market lately.

Gritstone bio Inc. (NASDAQ:GRTS) traded at $10.50 at close of the session on Monday, 11/29/21, made a downward move of -5.58% on its previous day’s price. Looking at the stock we see that its previous close was $11.12 and the beta (5Y monthly) reads 0.11 with the day’s price range being $10.3481 – $11.40. In … Are Investors Declined To Sell Their Gritstone bio Inc. (NASDAQ: GRTS) Holdings? Read More »

Gritstone bio Inc (NASDAQ: GRTS ) announced that the SARS-CoV-2 T cell epitopes (TCEs) administered within its self-amplifying mRNA (SAM) COVID-19 vaccines are minimally impacted by the Omicron (B.1.1.529) variant. Gritstone says that its second-generation SARS-CoV-2 vaccine platform delivers a stabilized Spike protein and highly conserved TCEs derived from other SARS-CoV-2 Full story available on Benzinga.com

State Street Corp increased its position in shares of Gritstone bio, Inc. (NASDAQ:GRTS) by 9.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 597,641 shares of the companys stock after purchasing an additional 53,519 shares during the quarter. State Street Corp owned []

Two sample Breakout Stocks for Week 48 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Daily Momentum Gauges® the port

Gritstone bio, Inc. (NASDAQ:GRTS) shares gapped up prior to trading on Friday . The stock had previously closed at $10.84, but opened at $11.18. Gritstone bio shares last traded at $11.34, with a volume of 1,990 shares traded. Several research firms recently commented on GRTS. HC Wainwright reiterated a buy rating and issued a $24.00 []

Price T Rowe Associates Inc. MD lessened its stake in Gritstone bio, Inc. (NASDAQ:GRTS) by 34.6% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 203,870 shares of the companys stock after selling 107,625 shares during the quarter. Price T Rowe Associates Inc. MDs holdings in Gritstone bio were worth $1,861,000 as of its []

EMERYVILLE, Calif., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immun